-
ICD-10-CM Codes
›
-
E00-E89
›
-
E20-E35
›
-
E26-
›
-
2023 ICD-10-CM Diagnosis Code E26.81
2023 ICD-10-CM Diagnosis Code E26.81
Bartter's syndrome
2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
- E26.81 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2023 edition of ICD-10-CM E26.81 became effective on October 1, 2022.
- This is the American ICD-10-CM version of E26.81 - other international versions of ICD-10 E26.81 may differ.
The following code(s) above
E26.81 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to
E26.81:
- Bartter syndrome
- Pseudoprimary hyperaldosteronism
Clinical Information
- A group of disorders caused by defective salt reabsorption in the ascending loop of henle. It is characterized by severe salt-wasting, hypokalemia; hypercalciuria; metabolic alkalosis, and hyper-reninemic hyperaldosteronism without hypertension. There are several subtypes including ones due to mutations in the renal specific sodium-potassium-chloride symporters.
- A rare inherited syndrome characterized by juxtaglomerular cell hyperplasia, hyperaldosteronism, hypokalemia, and alkalosis. Patients have high levels of plasma renin concentration which is not associated with hypertension.
- Hypertrophy and hyperplasia of the juxtaglomerular apparatus with secondary hyperaldosteronism with normal blood pressure and hyperkalemic alkalosis in the absence of edema. Most patients show growth and mental retardation. Nephrocalcinosis and hypercalcinuria occur in some cases. Diuretic abuse may produce a syndrome with similar characteristics (pseudo-bartter or factitious bartter syndrome).
- Transmitted as an autosomal recessive trait; characterized by hypertrophy and hyperplasia of the juxtaglomerular cells, and increased concentrations of renin, angiotensin ii, and aldosterone in the absence of edema and hypertension.
ICD-10-CM E26.81 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
- 643 Endocrine disorders with mcc
- 644 Endocrine disorders with cc
- 645 Endocrine disorders without cc/mcc
Convert E26.81 to ICD-9-CM
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
ICD-10-CM Codes Adjacent To E26.81
E25.0 Congenital adrenogenital disorders associated with enzyme deficiency
E25.8 Other adrenogenital disorders
E25.9 Adrenogenital disorder, unspecified
E26.0 Primary hyperaldosteronism
E26.02 Glucocorticoid-remediable aldosteronism
E26.09 Other primary hyperaldosteronism
E26.1 Secondary hyperaldosteronism
E26.8 Other hyperaldosteronism
E26.81
Bartter's syndrome
E26.89 Other hyperaldosteronism
E26.9 Hyperaldosteronism, unspecified
E27 Other disorders of adrenal gland
E27.0 Other adrenocortical overactivity
E27.1 Primary adrenocortical insufficiency
E27.3 Drug-induced adrenocortical insufficiency
E27.4 Other and unspecified adrenocortical insufficiency
E27.40 Unspecified adrenocortical insufficiency
E27.49 Other adrenocortical insufficiency
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
